Evidence method
Level · gp.fundamentals.debt_to_revenue
0.00% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
PBYI · Jun 30, 2026
PUMA BIOTECHNOLOGY, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001437749-26-026311General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
2.87% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
7.75% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
23.58% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
77.92% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
13.42% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.46% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History13 statesHistory building
Jun 30, 20230/5 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20255/8 normalizedLevel 3Sep 30, 20256/8 normalizedLevel 3Dec 31, 20256/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 25.31%
- Current
- 0.00%
- Delta
- -25.31%
- Previous
- 34.40%
- Current
- 2.87%
- Delta
- -31.53%
- Previous
- -2.59%
- Current
- 7.75%
- Delta
- 10.35%
- Previous
- 19.40%
- Current
- 23.58%
- Delta
- 4.18%
- Previous
- 76.74%
- Current
- 77.92%
- Delta
- 1.18%
- Previous
- -8.54%
- Current
- 13.42%
- Delta
- 21.97%
- Previous
- 4.23%
- Current
- 3.46%
- Delta
- -0.77%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Transitioned To · PBYI Fundamental State →Transitioned To · PBYI BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · PBYI CASH_GENERATION_DECREASED →Transitioned To · PBYI GROWTH_INCREASED →Transitioned To · PBYI INVENTORY_PRESSURE_INCREASED →Transitioned To · PBYI MARGIN_INCREASED →Transitioned To · PBYI PROFITABILITY_INCREASED →Transitioned To · PBYI SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.